Mirum Pharmaceuticals (MIRM) Reports Positive Phase 2b Data for Volixibat in PSC at EASL Congress
Mirum Pharmaceuticals reported Phase 2b results at the EASL Congress. In VISTAS, volixibat in primary sclerosing cholangitis reduced pruritus and the company plans an NDA submission in H2 2026. In AZURE-1, brelovitug in chronic hepatitis delta virus showed virologic response and ALT normalization at Week 24; Phase 3 topline data are expected later in 2026.
How this was made
The 30-second read
Why it matters
Positive congress readouts strengthen the regulatory narrative and can shift probability-weighted valuation toward H2 2026 NDA and 2027 BLA milestones; however, Phase 3 outcomes remain the key swing factor.
Market read
Material biotech catalyst tied to specific clinical programs and explicit regulatory submission windows.
What to watch
The article provides directional outcomes but omits key details (e.g., effect sizes, safety/tolerability specifics, statistical thresholds), which can matter for regulatory review and Phase 3 design.
Background
Mirum is advancing rare liver disease therapies: volixibat for PSC (VISTAS Phase 2b), brelovitug for HDV (AZURE-1 Phase 2b), and maralixibat (LIVMARLI) for PFIC.
Ticker impact
Mirum reported positive Phase 2b VISTAS (volixibat) and AZURE-1 (brelovitug) data at EASL, supporting planned NDA/BLA submissions.
Likely positive near-term bias as traders reprice regulatory odds and catalyst timing; magnitude depends on prior expectations.
The article cites specific, newly presented Phase 2b efficacy/safety outcomes and ties them directly to planned NDA/BLA submission windows.
Market effects
Supports sentiment for rare/orphan hepatology pipeline assets and can lift peer read-through on PSC/HDV competitive landscape.
Primarily US biotech sentiment; limited direct regional transmission mentioned.
EASL congress data is globally relevant for hepatology investors and can influence international biotech positioning.
Counterpoint
Phase 2b positivity may already be partially priced; without Phase 3 confirmation, upside could fade on valuation/expectations risk.
Key entities
- companyMirum Pharmaceuticals
Reported positive Phase 2b data for volixibat (PSC) and brelovitug (HDV) at EASL; reiterated planned NDA/BLA timing.
- drugvolixibat
Phase 2b VISTAS program in PSC; results described as rapid, sustained, clinically meaningful pruritus reductions.
- drugbrelovitug
Phase 2b AZURE-1 program in chronic HDV; described strong virologic response and ALT normalization at Week 24.
- drugLIVMARLI (maralixibat)
Real-world evidence in PFIC showing improved event-free survival vs external control cohort.
